Clinical Development, Dermatology and Manufacturing

Clinical Development

Dermatology

Manufacturing

KFA-115 by Novartis for Melanoma: Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 28, 2023

KFA-115 is under clinical development by Novartis and currently in Phase I for Melanoma. Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.

Generic Pharmaceutical

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials

(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Genital Warts (Condylomata Acuminata): Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). It was also under development for the treatment of cervical intraepithelial neoplasia caused by human papilloma virus.

Contract Manufacturing

Contract Manufacturing Dermatology Hormones Production

Join 21,000+

Insiders

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Trending Sources

(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Cervical Intraepithelial Neoplasia (CIN): Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). It was also under development for the treatment of cervical intraepithelial neoplasia caused by human papilloma virus.

Contract Manufacturing

Contract Manufacturing Dermatology Hormones Production

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

KFA-115 by Novartis for Malignant Mesothelioma: Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 28, 2023

KFA-115 is under clinical development by Novartis and currently in Phase I for Malignant Mesothelioma. Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.

Generic Pharmaceutical

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials

Iptacopan hydrochloride by Novartis for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 28, 2023

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Paroxysmal Nocturnal Hemoglobinuria. Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.

Generic Pharmaceutical

Generic Pharmaceutical Dermatology Drugs Clinical Trials

Iptacopan hydrochloride by Novartis for Glomerulonephritis: Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 28, 2023

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Glomerulonephritis. Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.

Generic Pharmaceutical

Generic Pharmaceutical Dermatology Drugs Clinical Trials

Risk adjusted net present value: What is the current valuation of Novartis’s Gevokizumab?

Pharmaceutical Technology

FEBRUARY 18, 2023

The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Gevokizumab Overview Gevokizumab (XOMA-052) is developing gevokizumab for the treatment of metastatic colorectal cancer gastroesophageal cancer and colon cancer.

Generic Pharmaceutical

Generic Pharmaceutical Dermatology Antibody Development

Crescita Announces Licensing Agreement for Pliaglis; in China

The Pharma Data

NOVEMBER 4, 2020

(TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing

Licensing Licensing Dermatology Production

BioSpace Movers & Shakers, Dec. 18

The Pharma Data

DECEMBER 17, 2020

Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Prior to joining Cidara, Kurtz served as head of commercial API manufacturing at Gilead Sciences.

Development

Development Gene Therapy Engineer Life Science

Pfizer Completes Acquisition of Arena Pharmaceuticals

The Pharma Data

MARCH 13, 2022

(NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.

Dermatology

Dermatology Cardiology Development Medicine

Top 7 Pharma Industry Leaders in 2020 By the Numbers

Delveinsight

AUGUST 25, 2021

The pharmaceutical industry finds, develops, manufactures, and promotes medicines or pharmaceutical drugs for usage as medications that are administered (or self-administered) to patients in order to cure, vaccinate, or relieve symptoms. Johnson and Johnson manufactures a variety of drugs to treat several indications.

Vaccination

Vaccination Vaccine Drugs Sales

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

The Pharma Data

SEPTEMBER 15, 2020

In addition to the COVID-19 vaccine program, Pfizer aims to deliver five innovative vaccines by 2025, subject to clinical success and regulatory approval. Three of the nine boys were dosed with gene therapy product that was manufactured using the commercial manufacturing process developed at Pfizer’s facility in Sanford, North Carolina.

Gene Therapy

Gene Therapy Vaccination Vaccine Trials

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. every eight weeks for the 90 mg dose, according to the manufacturer. per dose when given every three weeks, as reported by the manufacturer.

Sales

Sales Manufacturing FDA Approval Life Science

Safety Recommendation on Janus kinase (JAK) Inhibitors Issued in the European Union

Pfizer

OCTOBER 28, 2022

XELJANZ has been studied in more than 50 clinical trials worldwide, including more than 20 trials in rheumatoid arthritis (RA) patients, and prescribed to more than 362,000 adult patients (the majority of whom were RA patients) worldwide since 2012.

Clinical Trials

Clinical Trials Clinical Trials Vaccination Vaccine

Clinical Research Informer

KFA-115 by Novartis for Melanoma: Likelihood of Approval

(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Genital Warts (Condylomata Acuminata): Likelihood of Approval

Webinars

Trending Sources

(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Cervical Intraepithelial Neoplasia (CIN): Likelihood of Approval

Webinars

KFA-115 by Novartis for Malignant Mesothelioma: Likelihood of Approval

Iptacopan hydrochloride by Novartis for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval

Iptacopan hydrochloride by Novartis for Glomerulonephritis: Likelihood of Approval

Risk adjusted net present value: What is the current valuation of Novartis’s Gevokizumab?

Crescita Announces Licensing Agreement for Pliaglis; in China

BioSpace Movers & Shakers, Dec. 18

Pfizer Completes Acquisition of Arena Pharmaceuticals

Top 7 Pharma Industry Leaders in 2020 By the Numbers

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

Safety Recommendation on Janus kinase (JAK) Inhibitors Issued in the European Union

Stay Connected